✓ checked
trust me, bro:
here is the receipt.
the claim
Vaccines against COVID-19 variants require additional clinical trials
the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against
Is it true that vaccines against COVID-19 variants require additional clinical trials?
Yes. Clinical trials are routinely conducted to assess the safety, immunogenicity, and efficacy of COVID-19 vaccines updated to target newly emerging viral variants.
Verdict: SUPPORTED · 3 sources for, 0 against · Last checked
The analysis
The claim is a specific, empirically verifiable proposition regarding the regulatory and clinical development pathway for updated COVID-19 variant vaccines. Multiple retrieved papers describe ongoing phase 2 and phase III/II clinical trials specifically evaluating bivalent or variant-adapted COVID-19 vaccines (e.g., Papers 2, 4, 7), supporting the claim that new trials are conducted for these updated vaccines. Therefore, the balance verdict is SUPPORTED.
Evidence for · 3
Get citation
Branche, A., Rouphael, N., Diemert, D., Falsey, A., Losada, C., Baden, L., Frey, S., Whitaker, J., Little, S., Anderson, E., Walter, E., Novak, R., Rupp, R., Jackson, L., Babu, T., Kottkamp, A., Luetkemeyer, A., Immergluck, L., Presti, R., Bäcker, M., Winokur, P., Mahgoub, S., Goepfert, P., Fusco, D. N., Malkin, E., Bethony, J., Walsh, E., Graciaa, D., Samaha, H., Sherman, A., Walsh, S., Abate, G., Oikonomopoulou, Z., Sahly, H. M. E., Martin, T., Kamidani, S., Smith, M. J., Ladner, B., Porterfield, L., Dunstan, M., Wald, A., Davis, T., Atmar, R., Mulligan, M., Lyke, K. E., Posavad, C., Meagher, M., Stephens, D., Neuzil, K., Abebe, K., Hill, H., Albert, J., Telu, K., Mu, J., Lewis, T., Giebeig, L., Eaton, A., Netzl, A., Wilks, S., Türeli, S., Makhene, M., Crandon, S., Montefiori, D., Makowski, M., Smith, D. J., Nayak, S., Roberts, P., Beigel, J., Unterber, E. P. K. M. C. G. K. E. A. W. K. S. P. A., Walsh, E. E., Kingsley, P., Steinmetz, K., Peasley, M., Ackerley, C. G., Unterberger, K., Desrosiers, A., Siegel, M., Tong, A., Rooks, R., Hoft, D., Graham, I. L., Keitel, W., Healy, C., Carter, N., Hendrickx, S., Rostad, C., Peters, E., Nolan, L., Moody, M. A., Schmader, K., Wendrow, A., Herrick, J., Lau, R., Carste, B., Krause, T. M., Hauge, K., Engelson, C., Soma, V., Harris, C., Lopez, A. M., Johnson, E., Chan, A. W., Ali, F., Parker, T., O’Halloran, J. A., Thompson, R. M., Byrnes, K., Noor, A., Meier, J., Stapleton, J. T., Maxwell, C., Shami, S., Drouin, A., Numbi, F., McElrath, J., Gale, M., Baughman, H., McQuarrie, L., Engel, T. M., Griffith, C., McDonald, W., Burkey, A. E., Hoopengardner, L., Linton, J. E., Gettinger, N., Lee, M., Elsafy, M., Pikaart-Tautges, R., Arega, J., Hoang, B., Curtin, D., Koo, H., Sindall, E., Degrace, M., Post, D. J., Stephens, D., Neuzil, K., Farley, M. M., Marrazzo, J., Young, S., Lennox, J., Atmar, R., Mcneil, L. M., & Brown, E. R. (2023). Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. doi.org. https://doi.org/10.1038/s41591-023-02503-4
See more details
More for · 2
Get citation
Miranda, M. C., Kepl, E., Navarro, M., Chen, C., Johnson, M. R., Sprouse, K. R., Stewart, C., Palser, A., Valdez, A. S., Pettie, D., Sydeman, C., Ogohara, C., Kraft, J. C., Pham, M. N., Murphy, M., Wrenn, S. P., Fiala, B., Ravichandran, R., Ellis, D., Carter, L., Corti, D., Kellam, P., Lee, K. K., Walls, A., Veesler, D., & King, N. P. (2024). Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens. doi.org. https://doi.org/10.1038/s41541-024-00982-1
Get citation
Marc, G. P., Coria, L., Ceballos, A., Rodriguez, J. M., Lombardo, M., Bruno, L., Córdoba, F. P., Cassero, C. G. F., Salvatori, M., Medrano, M. R., Fulgenzi, F., Alzogaray, M. F., Mykietiuk, A., Uriarte, I. L., Itcovici, N., Casabella, T. S. S., Corral, G., Bruno, M., Roldán, O., Nuñez, S. A., Cahn, F., Yerino, G., Bianchi, A., Braem, V., Christmann, A., Corradetti, S., Darraidou, M. C., Nunzio, L. D., Estrada, T., Castelo, R. L., Marchionatti, C., Pitocco, L., Uriarte, V. T., Wood, C., Zadoff, R., Bues, F., Garrido, R. M., Montomoli, E., Manenti, A., Demaría, A., Prado, L., Castro, C. P., Saposnik, L., Geffner, J., Oca, F. M. d., Vega, J. C., Fló, J., Bonvehí, P., Cassará, J., Pasquevich, K., & Cassataro, J. (2025). Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial.. doi.org. https://doi.org/10.1016/j.vaccine.2025.127045
Related receipts
- Is it true that vaccine development requires many years of clinical testing and safety trials? SUPPORTED
- Is it true that participants in COVID-19 vaccine trials are intentionally exposed to the virus? SUPPORTED
- Is it true that natural immunity offers better protection against COVID-19 than mRNA vaccines for the same variant? SUPPORTED
- Is it true that more people have died from the COVID-19 vaccine than from COVID-19 itself? PARTIAL LEAN
- Is it true that COVID-19 vaccines require two doses at specific intervals to induce adequate immunity? SUPPORTED
- Is it true that COVID-19 vaccines increase the overall rate of infection? REFUTED
Receipt History
first checked04 Aug 2026
judged → SUPPORTED · 8604 Aug 2026
Anyone with this link can read the claim and its public receipt, including any
personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check
or guarantee a response time.
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work
Terms · Privacy · How verdicts work